Imperial Prostate

15/06/2026

We are staying local for this year in West London!

Imperial Prostate will be presenting 2️⃣ plenaries, 6️⃣ podiums & 5️⃣ posters with topics from uro-technology to screening to sustainability 🤖🌱

Looking forward to catching up with our collaborators, friends and colleagues! 💫

📅 Monday 15 June 2026

Impact of AI on Surgical Care
08:45-09:45 (Terence Millin)
📍 Digital Twins - Professor Rakesh Heer

Prostate Cancer
16:30-17:30 (Paddy O’Reilly)
📍 The added value of diffusion-weighted imaging and dynamic contrast- enhanced sequences in the diagnosis of localised radiorecurrent prostate cancer: an analysis from the FORECAST trial - Mr Alexander Light
📍 Variation in PSA testing rates across ethnic and socioeconomic groups in Northwest London - Mr Nikhil Mayor

Imperial College Healthcare NHS Trust | Imperial College London | Hashim Uddin Ahmed

12/06/2026

📣 The IP10-AVIDITY RCT is opening sites nationwide, currently recruiting from two main sites at Imperial College Healthcare NHS Trust and The Royal Marsden NHS Foundation Trust and identifying patients from Chelsea and Westminster Hospital NHS Foundation Trust and West Middlesex Hospital University Hospital

🌱 Current status: halfway through the embedded pilot phase

☎️ Contact us to join in widening patients' access to PSMA PET/CT

12/06/2026

The Prostate Imaging Standards for Screening Magnetic Resonance Imaging ( ): International Consensus Recommendations have just been published in JAMA Oncology 🗣️

⭐ 21 experts from 6 countries formed the recommendations
⭐ The PRISM recommendations provide wide-ranging guidance on the acquisition, reporting, and interpretation of in
⭐ Ongoing trials (including ) and screening pilots will be integral in validating the guidance
⭐ Read the Special Communication here:

This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening.

02/06/2026

We're expanding research, widening treatment options and tackling inequalities in prostate cancer care.

✅ All eligible Black men will be invited to join a landmark screening trial.

✅ A targeted NHS screening programme will also be rolled out.

More: https://www.gov.uk/government/news/major-expansion-of-research-and-treatment-for-prostate-cancer

02/06/2026

BIG NEWS 📢

The Government has announced up to £18 million in additional funding for TRANSFORM - recognising the crucial role our trial is playing in shaping the future of prostate cancer screening.

This investment means all eligible Black men aged 45 to 74 will be invited to take part in the trial, significantly increasing participation among men at higher risk.

It comes after the UK National Screening Committee’s final recommendation to screen only men with BRCA2 gene variations who also have a family history of the disease.

That’s why today’s additional funding marks a historic moment.

It will help us continue to generate the evidence needed for a safe, accurate and effective screening programme for all men.

➡️ Read more: bit.ly/4egex74

28/05/2026

For the first time, the UK National Screening Committee has recommended screening of prostate cancer.

The NSC recommends TARGETED screening to men with a BRCA2 gene mutation who also have a family history of prostate cancer. However, whole population screening is not recommended.

Read our survey on the views of UK urologists on screening published this month in BJUI and BJUI Compass journals here: https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70228?domain=p2p_domain&token=VWWGCCZYE5KXNIZJPZ5H

Hashim Uddin Ahmed Imperial College London Imperial College Healthcare NHS Trust

06/05/2026

🗞️ If you want to find out the latest on the study, watch this video message from the Chief Investigator Professor Hashim Uddin Ahmed on our YouTube channel ⬇️

https://youtu.be/lTeo7ITqyLA?si=1uMs16ydcnRyPP3d

If your centre is interested in joining the study or finding out more then send us a DM 📩

Find out the latest on the IP7-PACIFIC study

29/04/2026

We are delighted to share Professor Hashim Uddin Ahmed's feature in the latest issue of EMJ Urology.

Prof Ahmed discusses the role of MRI-led diagnostic pathways, the potential of AI to support clinical decision-making, the limitations of PSA-based screening and the need to reduce over diagnosis, as well as advances in focal therapy and personalised treatment strategies.

📖 Read the full interview: https://lnkd.in/gpaJ5EEi

29/04/2026

The IP10-AVIDITY trial is has welcomed Chelsea and Westminster Hospital at both Chelsea and West Middlesex sites as Participation Identification Centres, widening access to the trial across Northwest London to those with new diagnoses of high-risk prostate cancer.

If your centre is interested in joining this study, please contact us at [email protected]